Cargando…
Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 5...
Autores principales: | Bringans, Scott D., Ito, Jun, Stoll, Thomas, Winfield, Kaye, Phillips, Michael, Peters, Kirsten, Davis, Wendy A., Davis, Timothy M.E., Lipscombe, Richard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988498/ https://www.ncbi.nlm.nih.gov/pubmed/29900119 http://dx.doi.org/10.1016/j.euprot.2016.12.001 |
Ejemplares similares
-
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
por: Bringans, Scott, et al.
Publicado: (2020) -
PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020) -
A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease
por: Bringans, Scott, et al.
Publicado: (2020) -
Deep proteogenomics; high throughput gene validation by multidimensional liquid chromatography and mass spectrometry of proteins from the fungal wheat pathogen Stagonospora nodorum
por: Bringans, Scott, et al.
Publicado: (2009) -
Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
por: Peters, Kirsten E., et al.
Publicado: (2023)